Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2021

Open Access 01-05-2021 | Ultrasound

Massive pulmonary embolism in patients with extreme bleeding risk: a case series on the successful use of ultrasound-assisted, catheter directed thrombolysis in a district general hospital

Authors: Jingzhou He, Benjamin Clayton, Hibba Kurdi, Michael Gibbons, Anthony Watkinson, Andrew S. P. Sharp

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2021

Login to get access

Abstract

Massive pulmonary embolism (PE), characterised by profound arterial hypotension, is a life-threatening emergency with a 90-day mortality of over 50%. Systemic thrombolysis can significantly reduce the risk of death or cardiovascular collapse in these patients, by around 50%, but these benefits are offset by a fivefold increased risk of intracranial haemorrhage and major bleeding, which may limit its use in patients at high risk of catastrophic haemorrhage. We describe a case series of 3 patients presenting with massive PE, each with extreme risk of bleeding and contra-indication to systemic thrombolysis, treated successfully with ultrasound-assisted, catheter directed thrombolysis (U-ACDT). Our experience of this novel technique using the EkoSonic Endovascular System (Ekos, BTG, London, UK) on carefully selected patients has demonstrated the potential to improve clinical status in shocked patients, with minimal bleed risk. There have been several clinical studies evaluating the Ekos system. Both the ULTIMA and SEATTLE II studies have shown significant reductions in RV/LV ratio by CT scanning when compared to standard anticoagulation in patients with intermediate-risk PE, with minimal bleeding complications. However, there is a pressing need for a randomised trial demonstrating improvement in robust clinical outcomes when comparing U-ACDT to simple anticoagulation. We believe that this case series adds new insight and highlights the potential of catheter directed thrombolysis in this high-risk patient cohort and consideration should be made to its use in cases where systemic thrombolysis is felt to be too high risk.
Literature
1.
go back to reference Wan S, Quinlan DJ, Agnelli G, Eikelboom JW (2004) Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 110(6):744–749CrossRef Wan S, Quinlan DJ, Agnelli G, Eikelboom JW (2004) Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 110(6):744–749CrossRef
2.
go back to reference Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P et al (2014) Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 311(23):2414–2421CrossRef Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P et al (2014) Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 311(23):2414–2421CrossRef
3.
go back to reference Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M et al (2015) Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 36(10):605–614CrossRef Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M et al (2015) Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 36(10):605–614CrossRef
4.
go back to reference The Brain Resuscitation Clinical Trial II Study Group (1991) A randomized clinical trial of calcium entry blocker administration to comatose survivors of cardiac arrest: design, methods, and patient characteristics. Control Clin Trials 12(4):525–545CrossRef The Brain Resuscitation Clinical Trial II Study Group (1991) A randomized clinical trial of calcium entry blocker administration to comatose survivors of cardiac arrest: design, methods, and patient characteristics. Control Clin Trials 12(4):525–545CrossRef
5.
go back to reference Konstantinides SV, Barco S, Lankeit M, Meyer G (2016) Management of pulmonary embolism: an update. J Am Coll Cardiol 67(8):976–990CrossRef Konstantinides SV, Barco S, Lankeit M, Meyer G (2016) Management of pulmonary embolism: an update. J Am Coll Cardiol 67(8):976–990CrossRef
6.
go back to reference Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e496SCrossRef Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e496SCrossRef
7.
go back to reference Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P et al (2019) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 54(3):1901647CrossRef Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P et al (2019) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 54(3):1901647CrossRef
8.
go back to reference Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J et al (2014) Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 370(15):1402–1411CrossRef Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J et al (2014) Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 370(15):1402–1411CrossRef
9.
go back to reference Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Simon J, Gibbs R et al (2014) 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 35(43):3033–3073CrossRef Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Simon J, Gibbs R et al (2014) 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 35(43):3033–3073CrossRef
10.
go back to reference Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123(16):1788–1830CrossRef Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123(16):1788–1830CrossRef
11.
go back to reference Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464CrossRef Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464CrossRef
12.
go back to reference Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723CrossRef Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723CrossRef
13.
go back to reference Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJM (2008) Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 6(4):632–637CrossRef Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJM (2008) Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 6(4):632–637CrossRef
14.
go back to reference Bajaj NS, Kalra R, Arora P, Ather S, Guichard JL, Lancaster WJ et al (2016) Catheter-directed treatment for acute pulmonary embolism: systematic review and single-arm meta-analyses. Int J Cardiol 15(225):128–139CrossRef Bajaj NS, Kalra R, Arora P, Ather S, Guichard JL, Lancaster WJ et al (2016) Catheter-directed treatment for acute pulmonary embolism: systematic review and single-arm meta-analyses. Int J Cardiol 15(225):128–139CrossRef
15.
go back to reference Verstraete M, Miller GA, Bounameaux H, Charbonnier B, Colle JP, Lecorf G et al (1988) Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 77(2):353–360CrossRef Verstraete M, Miller GA, Bounameaux H, Charbonnier B, Colle JP, Lecorf G et al (1988) Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 77(2):353–360CrossRef
16.
go back to reference Braaten JV, Goss RA, Francis CW (1997) Ultrasound reversibly disaggregates fibrin fibers. Thromb Haemost 78(3):1063–1068CrossRef Braaten JV, Goss RA, Francis CW (1997) Ultrasound reversibly disaggregates fibrin fibers. Thromb Haemost 78(3):1063–1068CrossRef
17.
go back to reference Francis CW, Blinc A, Lee S, Cox C (1995) Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol 21(3):419–424CrossRef Francis CW, Blinc A, Lee S, Cox C (1995) Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol 21(3):419–424CrossRef
18.
go back to reference Kucher N, Boekstegers P, Müller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T et al (2014) Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 129(4):479–486CrossRef Kucher N, Boekstegers P, Müller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T et al (2014) Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 129(4):479–486CrossRef
19.
go back to reference Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM et al (2015) A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism. JACC Cardiovasc Interv 8(10):1382–1392CrossRef Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM et al (2015) A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism. JACC Cardiovasc Interv 8(10):1382–1392CrossRef
20.
go back to reference Tapson VF, Sterling K, Jones N, Elder M, Tripathy U, Brower J et al (2018) A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism. JACC Cardiovasc Interv 11(14):1401–1410CrossRef Tapson VF, Sterling K, Jones N, Elder M, Tripathy U, Brower J et al (2018) A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism. JACC Cardiovasc Interv 11(14):1401–1410CrossRef
Metadata
Title
Massive pulmonary embolism in patients with extreme bleeding risk: a case series on the successful use of ultrasound-assisted, catheter directed thrombolysis in a district general hospital
Authors
Jingzhou He
Benjamin Clayton
Hibba Kurdi
Michael Gibbons
Anthony Watkinson
Andrew S. P. Sharp
Publication date
01-05-2021
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02258-6

Other articles of this Issue 4/2021

Journal of Thrombosis and Thrombolysis 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine